Simplify VettaFi Private Credit Strategy ETF
Simplify VettaFi Private Credit Strategy ETF (PCR) Stock Competitors & Peer Comparison
See (PCR) competitors and their performances in Stock Market.
Peer Comparison Table: Asset Management - Income Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PCR | $20.47 | -1.21% | 2.2M | N/A | N/A | +6.60% |
| PONPX | $10.88 | +0.09% | 225B | N/A | N/A | N/A |
| PIMIX | $10.88 | +0.09% | 225B | N/A | N/A | N/A |
| PONAX | $10.88 | +0.09% | 224.8B | N/A | N/A | N/A |
| AMECX | $27.45 | -0.54% | 141.6B | 19.26 | $1.42 | +9.49% |
| RIDGX | $27.47 | -0.54% | 141.4B | 19.27 | $1.42 | N/A |
| IFAFX | $27.34 | -0.55% | 141.3B | 19.26 | $1.42 | +16.49% |
| RWICX | $79.55 | -0.06% | 139.9B | 24.52 | $3.21 | N/A |
| CWIAX | $79.94 | -0.06% | 138.3B | 24.52 | $3.22 | N/A |
| CWGFX | $80.09 | -0.06% | 136.7B | 24.52 | $3.23 | N/A |
Stock Comparison
PCR vs PONPX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PONPX has a market cap of 225B. Regarding current trading prices, PCR is priced at $20.47, while PONPX trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PONPX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to PONPX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PONPX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PONPX's competition here
PCR vs PIMIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PIMIX has a market cap of 225B. Regarding current trading prices, PCR is priced at $20.47, while PIMIX trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PIMIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to PIMIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PIMIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PIMIX's competition here
PCR vs PONAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PONAX has a market cap of 224.8B. Regarding current trading prices, PCR is priced at $20.47, while PONAX trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PONAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to PONAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PONAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PONAX's competition here
PCR vs AMECX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, AMECX has a market cap of 141.6B. Regarding current trading prices, PCR is priced at $20.47, while AMECX trades at $27.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas AMECX's P/E ratio is 19.26. In terms of profitability, PCR's ROE is +0.00%, compared to AMECX's ROE of +0.07%. Regarding short-term risk, PCR is more volatile compared to AMECX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check AMECX's competition here
PCR vs RIDGX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, RIDGX has a market cap of 141.4B. Regarding current trading prices, PCR is priced at $20.47, while RIDGX trades at $27.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas RIDGX's P/E ratio is 19.27. In terms of profitability, PCR's ROE is +0.00%, compared to RIDGX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to RIDGX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check RIDGX's competition here
PCR vs IFAFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, IFAFX has a market cap of 141.3B. Regarding current trading prices, PCR is priced at $20.47, while IFAFX trades at $27.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas IFAFX's P/E ratio is 19.26. In terms of profitability, PCR's ROE is +0.00%, compared to IFAFX's ROE of +0.07%. Regarding short-term risk, PCR is more volatile compared to IFAFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check IFAFX's competition here
PCR vs RWICX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, RWICX has a market cap of 139.9B. Regarding current trading prices, PCR is priced at $20.47, while RWICX trades at $79.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas RWICX's P/E ratio is 24.52. In terms of profitability, PCR's ROE is +0.00%, compared to RWICX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to RWICX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check RWICX's competition here
PCR vs CWIAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CWIAX has a market cap of 138.3B. Regarding current trading prices, PCR is priced at $20.47, while CWIAX trades at $79.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CWIAX's P/E ratio is 24.52. In terms of profitability, PCR's ROE is +0.00%, compared to CWIAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CWIAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CWIAX's competition here
PCR vs CWGFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CWGFX has a market cap of 136.7B. Regarding current trading prices, PCR is priced at $20.47, while CWGFX trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CWGFX's P/E ratio is 24.52. In terms of profitability, PCR's ROE is +0.00%, compared to CWGFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CWGFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CWGFX's competition here
PCR vs CWGIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CWGIX has a market cap of 136.7B. Regarding current trading prices, PCR is priced at $20.47, while CWGIX trades at $80.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CWGIX's P/E ratio is 24.52. In terms of profitability, PCR's ROE is +0.00%, compared to CWGIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CWGIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CWGIX's competition here
PCR vs CIBFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CIBFX has a market cap of 121.3B. Regarding current trading prices, PCR is priced at $20.47, while CIBFX trades at $81.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CIBFX's P/E ratio is 19.76. In terms of profitability, PCR's ROE is +0.00%, compared to CIBFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CIBFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CIBFX's competition here
PCR vs CAIBX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CAIBX has a market cap of 121.2B. Regarding current trading prices, PCR is priced at $20.47, while CAIBX trades at $81.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CAIBX's P/E ratio is 19.76. In terms of profitability, PCR's ROE is +0.00%, compared to CAIBX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CAIBX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CAIBX's competition here
PCR vs RIRGX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, RIRGX has a market cap of 121.2B. Regarding current trading prices, PCR is priced at $20.47, while RIRGX trades at $81.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas RIRGX's P/E ratio is 19.77. In terms of profitability, PCR's ROE is +0.00%, compared to RIRGX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to RIRGX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check RIRGX's competition here
PCR vs CIRAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CIRAX has a market cap of 120B. Regarding current trading prices, PCR is priced at $20.47, while CIRAX trades at $81.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CIRAX's P/E ratio is 19.76. In terms of profitability, PCR's ROE is +0.00%, compared to CIRAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CIRAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CIRAX's competition here
PCR vs DODIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, DODIX has a market cap of 107.5B. Regarding current trading prices, PCR is priced at $20.47, while DODIX trades at $12.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas DODIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to DODIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to DODIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check DODIX's competition here
PCR vs FNCFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FNCFX has a market cap of 79.5B. Regarding current trading prices, PCR is priced at $20.47, while FNCFX trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FNCFX's P/E ratio is 21.45. In terms of profitability, PCR's ROE is +0.00%, compared to FNCFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to FNCFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FNCFX's competition here
PCR vs FKINX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FKINX has a market cap of 78.3B. Regarding current trading prices, PCR is priced at $20.47, while FKINX trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FKINX's P/E ratio is 21.37. In terms of profitability, PCR's ROE is +0.00%, compared to FKINX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to FKINX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FKINX's competition here
PCR vs VEIRX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VEIRX has a market cap of 62B. Regarding current trading prices, PCR is priced at $20.47, while VEIRX trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VEIRX's P/E ratio is 15.84. In terms of profitability, PCR's ROE is +0.00%, compared to VEIRX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VEIRX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VEIRX's competition here
PCR vs VEIPX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VEIPX has a market cap of 61.7B. Regarding current trading prices, PCR is priced at $20.47, while VEIPX trades at $46.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VEIPX's P/E ratio is 15.84. In terms of profitability, PCR's ROE is +0.00%, compared to VEIPX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VEIPX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VEIPX's competition here
PCR vs VWINX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VWINX has a market cap of 48.2B. Regarding current trading prices, PCR is priced at $20.47, while VWINX trades at $25.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VWINX's P/E ratio is 16.00. In terms of profitability, PCR's ROE is +0.00%, compared to VWINX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VWINX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VWINX's competition here
PCR vs VWIAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VWIAX has a market cap of 47.4B. Regarding current trading prices, PCR is priced at $20.47, while VWIAX trades at $62.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VWIAX's P/E ratio is 16.00. In terms of profitability, PCR's ROE is +0.00%, compared to VWIAX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VWIAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VWIAX's competition here
PCR vs JEPI Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JEPI has a market cap of 45.2B. Regarding current trading prices, PCR is priced at $20.47, while JEPI trades at $55.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JEPI's P/E ratio is 26.66. In terms of profitability, PCR's ROE is +0.00%, compared to JEPI's ROE of +0.00%. Regarding short-term risk, PCR is less volatile compared to JEPI. This indicates potentially lower risk in terms of short-term price fluctuations for PCR.Check JEPI's competition here
PCR vs LDLVX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, LDLVX has a market cap of 43B. Regarding current trading prices, PCR is priced at $20.47, while LDLVX trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas LDLVX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to LDLVX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to LDLVX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check LDLVX's competition here
PCR vs HLIEX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HLIEX has a market cap of 42.8B. Regarding current trading prices, PCR is priced at $20.47, while HLIEX trades at $26.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HLIEX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HLIEX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HLIEX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HLIEX's competition here
PCR vs LLDYX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, LLDYX has a market cap of 42.5B. Regarding current trading prices, PCR is priced at $20.47, while LLDYX trades at $3.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas LLDYX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to LLDYX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to LLDYX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check LLDYX's competition here
PCR vs OIEJX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, OIEJX has a market cap of 41.2B. Regarding current trading prices, PCR is priced at $20.47, while OIEJX trades at $26.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas OIEJX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to OIEJX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to OIEJX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check OIEJX's competition here
PCR vs JEPQ Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JEPQ has a market cap of 38B. Regarding current trading prices, PCR is priced at $20.47, while JEPQ trades at $59.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JEPQ's P/E ratio is 32.69. In terms of profitability, PCR's ROE is +0.00%, compared to JEPQ's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to JEPQ. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JEPQ's competition here
PCR vs JPST Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JPST has a market cap of 37.7B. Regarding current trading prices, PCR is priced at $20.47, while JPST trades at $50.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JPST's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JPST's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JPST. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JPST's competition here
PCR vs VTINX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VTINX has a market cap of 36B. Regarding current trading prices, PCR is priced at $20.47, while VTINX trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VTINX's P/E ratio is 21.71. In terms of profitability, PCR's ROE is +0.00%, compared to VTINX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to VTINX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VTINX's competition here
PCR vs AHTFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, AHTFX has a market cap of 27.4B. Regarding current trading prices, PCR is priced at $20.47, while AHTFX trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas AHTFX's P/E ratio is 48.97. In terms of profitability, PCR's ROE is +0.00%, compared to AHTFX's ROE of -0.09%. Regarding short-term risk, PCR is more volatile compared to AHTFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check AHTFX's competition here
PCR vs PRFDX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PRFDX has a market cap of 27.3B. Regarding current trading prices, PCR is priced at $20.47, while PRFDX trades at $42.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PRFDX's P/E ratio is 21.63. In terms of profitability, PCR's ROE is +0.00%, compared to PRFDX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PRFDX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PRFDX's competition here
PCR vs TIBIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBIX has a market cap of 26.3B. Regarding current trading prices, PCR is priced at $20.47, while TIBIX trades at $38.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBIX's P/E ratio is 4.63. In terms of profitability, PCR's ROE is +0.00%, compared to TIBIX's ROE of +0.01%. Regarding short-term risk, PCR is more volatile compared to TIBIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBIX's competition here
PCR vs TIBMX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBMX has a market cap of 26.3B. Regarding current trading prices, PCR is priced at $20.47, while TIBMX trades at $38.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBMX's P/E ratio is 4.63. In terms of profitability, PCR's ROE is +0.00%, compared to TIBMX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TIBMX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBMX's competition here
PCR vs TIBGX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBGX has a market cap of 26.1B. Regarding current trading prices, PCR is priced at $20.47, while TIBGX trades at $37.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBGX's P/E ratio is 4.60. In terms of profitability, PCR's ROE is +0.00%, compared to TIBGX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TIBGX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBGX's competition here
PCR vs TIBAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBAX has a market cap of 26.1B. Regarding current trading prices, PCR is priced at $20.47, while TIBAX trades at $37.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBAX's P/E ratio is 4.59. In terms of profitability, PCR's ROE is +0.00%, compared to TIBAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TIBAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBAX's competition here
PCR vs TIBRX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBRX has a market cap of 26.1B. Regarding current trading prices, PCR is priced at $20.47, while TIBRX trades at $37.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBRX's P/E ratio is 4.59. In terms of profitability, PCR's ROE is +0.00%, compared to TIBRX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TIBRX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBRX's competition here
PCR vs TIBCX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TIBCX has a market cap of 26.1B. Regarding current trading prices, PCR is priced at $20.47, while TIBCX trades at $37.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TIBCX's P/E ratio is 4.58. In terms of profitability, PCR's ROE is +0.00%, compared to TIBCX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TIBCX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TIBCX's competition here
PCR vs GAIFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, GAIFX has a market cap of 21.5B. Regarding current trading prices, PCR is priced at $20.47, while GAIFX trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas GAIFX's P/E ratio is 25.07. In terms of profitability, PCR's ROE is +0.00%, compared to GAIFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to GAIFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check GAIFX's competition here
PCR vs MIAWX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, MIAWX has a market cap of 21.3B. Regarding current trading prices, PCR is priced at $20.47, while MIAWX trades at $9.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas MIAWX's P/E ratio is 55.24. In terms of profitability, PCR's ROE is +0.00%, compared to MIAWX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to MIAWX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check MIAWX's competition here
PCR vs IGIFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, IGIFX has a market cap of 19.1B. Regarding current trading prices, PCR is priced at $20.47, while IGIFX trades at $49.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas IGIFX's P/E ratio is 18.72. In terms of profitability, PCR's ROE is +0.00%, compared to IGIFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to IGIFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check IGIFX's competition here
PCR vs PFIAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PFIAX has a market cap of 18.4B. Regarding current trading prices, PCR is priced at $20.47, while PFIAX trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PFIAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to PFIAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PFIAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PFIAX's competition here
PCR vs PFIIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PFIIX has a market cap of 18.4B. Regarding current trading prices, PCR is priced at $20.47, while PFIIX trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PFIIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to PFIIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PFIIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PFIIX's competition here
PCR vs VGIAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VGIAX has a market cap of 18B. Regarding current trading prices, PCR is priced at $20.47, while VGIAX trades at $117.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VGIAX's P/E ratio is 24.18. In terms of profitability, PCR's ROE is +0.00%, compared to VGIAX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VGIAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VGIAX's competition here
PCR vs ESIIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, ESIIX has a market cap of 17.7B. Regarding current trading prices, PCR is priced at $20.47, while ESIIX trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas ESIIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to ESIIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to ESIIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check ESIIX's competition here
PCR vs PRCIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PRCIX has a market cap of 17.6B. Regarding current trading prices, PCR is priced at $20.47, while PRCIX trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PRCIX's P/E ratio is 30.50. In terms of profitability, PCR's ROE is +0.00%, compared to PRCIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PRCIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PRCIX's competition here
PCR vs PRXEX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PRXEX has a market cap of 17.5B. Regarding current trading prices, PCR is priced at $20.47, while PRXEX trades at $7.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PRXEX's P/E ratio is 30.50. In terms of profitability, PCR's ROE is +0.00%, compared to PRXEX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PRXEX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PRXEX's competition here
PCR vs VQNPX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, VQNPX has a market cap of 16.6B. Regarding current trading prices, PCR is priced at $20.47, while VQNPX trades at $71.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas VQNPX's P/E ratio is 24.17. In terms of profitability, PCR's ROE is +0.00%, compared to VQNPX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to VQNPX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check VQNPX's competition here
PCR vs COSIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, COSIX has a market cap of 16.4B. Regarding current trading prices, PCR is priced at $20.47, while COSIX trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas COSIX's P/E ratio is 24.92. In terms of profitability, PCR's ROE is +0.00%, compared to COSIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to COSIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check COSIX's competition here
PCR vs BLPFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, BLPFX has a market cap of 16B. Regarding current trading prices, PCR is priced at $20.47, while BLPFX trades at $21.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas BLPFX's P/E ratio is 23.66. In terms of profitability, PCR's ROE is +0.00%, compared to BLPFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to BLPFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check BLPFX's competition here
PCR vs FAGIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FAGIX has a market cap of 15.7B. Regarding current trading prices, PCR is priced at $20.47, while FAGIX trades at $11.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FAGIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FAGIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to FAGIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FAGIX's competition here
PCR vs FADMX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FADMX has a market cap of 15.4B. Regarding current trading prices, PCR is priced at $20.47, while FADMX trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FADMX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FADMX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to FADMX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FADMX's competition here
PCR vs FGRIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FGRIX has a market cap of 14.7B. Regarding current trading prices, PCR is priced at $20.47, while FGRIX trades at $72.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FGRIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FGRIX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to FGRIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FGRIX's competition here
PCR vs ABHFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, ABHFX has a market cap of 14.2B. Regarding current trading prices, PCR is priced at $20.47, while ABHFX trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas ABHFX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to ABHFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to ABHFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check ABHFX's competition here
PCR vs FLTMX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FLTMX has a market cap of 14.2B. Regarding current trading prices, PCR is priced at $20.47, while FLTMX trades at $10.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FLTMX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FLTMX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to FLTMX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FLTMX's competition here
PCR vs FFRHX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FFRHX has a market cap of 13.8B. Regarding current trading prices, PCR is priced at $20.47, while FFRHX trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FFRHX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FFRHX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to FFRHX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FFRHX's competition here
PCR vs ACEIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, ACEIX has a market cap of 12.5B. Regarding current trading prices, PCR is priced at $20.47, while ACEIX trades at $11.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas ACEIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to ACEIX's ROE of -0.30%. Regarding short-term risk, PCR is more volatile compared to ACEIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check ACEIX's competition here
PCR vs FEQIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FEQIX has a market cap of 11.5B. Regarding current trading prices, PCR is priced at $20.47, while FEQIX trades at $89.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FEQIX's P/E ratio is 20.93. In terms of profitability, PCR's ROE is +0.00%, compared to FEQIX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to FEQIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FEQIX's competition here
PCR vs HBLVX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HBLVX has a market cap of 11.3B. Regarding current trading prices, PCR is priced at $20.47, while HBLVX trades at $15.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HBLVX's P/E ratio is 21.87. In terms of profitability, PCR's ROE is +0.00%, compared to HBLVX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HBLVX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HBLVX's competition here
PCR vs HBLTX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HBLTX has a market cap of 11.2B. Regarding current trading prices, PCR is priced at $20.47, while HBLTX trades at $14.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HBLTX's P/E ratio is 21.88. In terms of profitability, PCR's ROE is +0.00%, compared to HBLTX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HBLTX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HBLTX's competition here
PCR vs HBLRX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HBLRX has a market cap of 11.1B. Regarding current trading prices, PCR is priced at $20.47, while HBLRX trades at $14.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HBLRX's P/E ratio is 21.86. In terms of profitability, PCR's ROE is +0.00%, compared to HBLRX's ROE of -0.12%. Regarding short-term risk, PCR is more volatile compared to HBLRX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HBLRX's competition here
PCR vs TSIIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TSIIX has a market cap of 10.1B. Regarding current trading prices, PCR is priced at $20.47, while TSIIX trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TSIIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to TSIIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TSIIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TSIIX's competition here
PCR vs DFCF Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, DFCF has a market cap of 10.1B. Regarding current trading prices, PCR is priced at $20.47, while DFCF trades at $42.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas DFCF's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to DFCF's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to DFCF. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check DFCF's competition here
PCR vs JSOAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JSOAX has a market cap of 9.6B. Regarding current trading prices, PCR is priced at $20.47, while JSOAX trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JSOAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JSOAX's ROE of +0.10%. Regarding short-term risk, PCR is more volatile compared to JSOAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JSOAX's competition here
PCR vs SPYI Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, SPYI has a market cap of 9.3B. Regarding current trading prices, PCR is priced at $20.47, while SPYI trades at $53.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas SPYI's P/E ratio is 27.46. In terms of profitability, PCR's ROE is +0.00%, compared to SPYI's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to SPYI. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check SPYI's competition here
PCR vs INPFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, INPFX has a market cap of 9.3B. Regarding current trading prices, PCR is priced at $20.47, while INPFX trades at $14.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas INPFX's P/E ratio is 21.96. In terms of profitability, PCR's ROE is +0.00%, compared to INPFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to INPFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check INPFX's competition here
PCR vs PQIAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PQIAX has a market cap of 8.1B. Regarding current trading prices, PCR is priced at $20.47, while PQIAX trades at $44.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PQIAX's P/E ratio is 24.19. In terms of profitability, PCR's ROE is +0.00%, compared to PQIAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to PQIAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check PQIAX's competition here
PCR vs FETKX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FETKX has a market cap of 8.1B. Regarding current trading prices, PCR is priced at $20.47, while FETKX trades at $31.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FETKX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FETKX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to FETKX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FETKX's competition here
PCR vs FEQTX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, FEQTX has a market cap of 8.1B. Regarding current trading prices, PCR is priced at $20.47, while FEQTX trades at $31.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas FEQTX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to FEQTX's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to FEQTX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check FEQTX's competition here
PCR vs NSTLX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, NSTLX has a market cap of 8B. Regarding current trading prices, PCR is priced at $20.47, while NSTLX trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas NSTLX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to NSTLX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to NSTLX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check NSTLX's competition here
PCR vs PDI Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, PDI has a market cap of 7.7B. Regarding current trading prices, PCR is priced at $20.47, while PDI trades at $17.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas PDI's P/E ratio is 8.59. In terms of profitability, PCR's ROE is +0.00%, compared to PDI's ROE of +0.11%. Regarding short-term risk, PCR is less volatile compared to PDI. This indicates potentially lower risk in terms of short-term price fluctuations for PCR.Check PDI's competition here
PCR vs JGINX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JGINX has a market cap of 7.7B. Regarding current trading prices, PCR is priced at $20.47, while JGINX trades at $75.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JGINX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JGINX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JGINX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JGINX's competition here
PCR vs JADGX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JADGX has a market cap of 7.7B. Regarding current trading prices, PCR is priced at $20.47, while JADGX trades at $75.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JADGX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JADGX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JADGX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JADGX's competition here
PCR vs JDNNX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JDNNX has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while JDNNX trades at $75.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JDNNX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JDNNX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JDNNX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JDNNX's competition here
PCR vs JAGIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JAGIX has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while JAGIX trades at $75.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JAGIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JAGIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JAGIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JAGIX's competition here
PCR vs JGICX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JGICX has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while JGICX trades at $73.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JGICX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JGICX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JGICX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JGICX's competition here
PCR vs JDNRX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JDNRX has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while JDNRX trades at $74.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JDNRX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JDNRX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JDNRX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JDNRX's competition here
PCR vs CGCP Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CGCP has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while CGCP trades at $22.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CGCP's P/E ratio is 10.91. In terms of profitability, PCR's ROE is +0.00%, compared to CGCP's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to CGCP. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CGCP's competition here
PCR vs JDNAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JDNAX has a market cap of 7.6B. Regarding current trading prices, PCR is priced at $20.47, while JDNAX trades at $75.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JDNAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JDNAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JDNAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JDNAX's competition here
PCR vs HFQSX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQSX has a market cap of 7.4B. Regarding current trading prices, PCR is priced at $20.47, while HFQSX trades at $7.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQSX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQSX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQSX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQSX's competition here
PCR vs HFQRX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQRX has a market cap of 7.4B. Regarding current trading prices, PCR is priced at $20.47, while HFQRX trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQRX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQRX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQRX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQRX's competition here
PCR vs HFQTX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQTX has a market cap of 7.3B. Regarding current trading prices, PCR is priced at $20.47, while HFQTX trades at $7.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQTX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQTX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQTX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQTX's competition here
PCR vs HFQAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQAX has a market cap of 7.3B. Regarding current trading prices, PCR is priced at $20.47, while HFQAX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQAX's competition here
PCR vs HFQIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQIX has a market cap of 7.3B. Regarding current trading prices, PCR is priced at $20.47, while HFQIX trades at $7.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQIX's competition here
PCR vs HFQCX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, HFQCX has a market cap of 7.3B. Regarding current trading prices, PCR is priced at $20.47, while HFQCX trades at $7.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas HFQCX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to HFQCX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to HFQCX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check HFQCX's competition here
PCR vs CPXAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, CPXAX has a market cap of 7.1B. Regarding current trading prices, PCR is priced at $20.47, while CPXAX trades at $12.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas CPXAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to CPXAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to CPXAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check CPXAX's competition here
PCR vs JMUIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMUIX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMUIX trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMUIX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMUIX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMUIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMUIX's competition here
PCR vs JMUTX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMUTX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMUTX trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMUTX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMUTX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMUTX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMUTX's competition here
PCR vs JMTNX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMTNX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMTNX trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMTNX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMTNX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMTNX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMTNX's competition here
PCR vs JMUCX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMUCX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMUCX trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMUCX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMUCX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMUCX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMUCX's competition here
PCR vs JMUAX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMUAX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMUAX trades at $8.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMUAX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMUAX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMUAX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMUAX's competition here
PCR vs JMUSX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMUSX has a market cap of 7B. Regarding current trading prices, PCR is priced at $20.47, while JMUSX trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMUSX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMUSX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to JMUSX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMUSX's competition here
PCR vs JMTG Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMTG has a market cap of 6.9B. Regarding current trading prices, PCR is priced at $20.47, while JMTG trades at $50.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMTG's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMTG's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to JMTG. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMTG's competition here
PCR vs DLFNX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, DLFNX has a market cap of 6.8B. Regarding current trading prices, PCR is priced at $20.47, while DLFNX trades at $9.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas DLFNX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to DLFNX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to DLFNX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check DLFNX's competition here
PCR vs DIVO Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, DIVO has a market cap of 6.6B. Regarding current trading prices, PCR is priced at $20.47, while DIVO trades at $45.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas DIVO's P/E ratio is 23.98. In terms of profitability, PCR's ROE is +0.00%, compared to DIVO's ROE of +0.00%. Regarding short-term risk, PCR is less volatile compared to DIVO. This indicates potentially lower risk in terms of short-term price fluctuations for PCR.Check DIVO's competition here
PCR vs TGIHX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TGIHX has a market cap of 6.6B. Regarding current trading prices, PCR is priced at $20.47, while TGIHX trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TGIHX's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to TGIHX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TGIHX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TGIHX's competition here
PCR vs TWEIX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TWEIX has a market cap of 6.4B. Regarding current trading prices, PCR is priced at $20.47, while TWEIX trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TWEIX's P/E ratio is 20.21. In terms of profitability, PCR's ROE is +0.00%, compared to TWEIX's ROE of +0.35%. Regarding short-term risk, PCR is more volatile compared to TWEIX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TWEIX's competition here
PCR vs AEUDX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, AEUDX has a market cap of 6.4B. Regarding current trading prices, PCR is priced at $20.47, while AEUDX trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas AEUDX's P/E ratio is 20.21. In terms of profitability, PCR's ROE is +0.00%, compared to AEUDX's ROE of +0.35%. Regarding short-term risk, PCR is more volatile compared to AEUDX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check AEUDX's competition here
PCR vs JMST Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, JMST has a market cap of 6.2B. Regarding current trading prices, PCR is priced at $20.47, while JMST trades at $50.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas JMST's P/E ratio is N/A. In terms of profitability, PCR's ROE is +0.00%, compared to JMST's ROE of +0.00%. Regarding short-term risk, PCR is more volatile compared to JMST. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check JMST's competition here
PCR vs TAIFX Comparison May 2026
PCR plays a significant role within the Financial Services sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PCR stands at 2.2M. In comparison, TAIFX has a market cap of 6.2B. Regarding current trading prices, PCR is priced at $20.47, while TAIFX trades at $17.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PCR currently has a P/E ratio of N/A, whereas TAIFX's P/E ratio is 23.98. In terms of profitability, PCR's ROE is +0.00%, compared to TAIFX's ROE of N/A. Regarding short-term risk, PCR is more volatile compared to TAIFX. This indicates potentially higher risk in terms of short-term price fluctuations for PCR.Check TAIFX's competition here